文献速递血液透析通路

动力学血管内微切开联合普通球囊成形术在真实世界血透通路功能障碍中的应用

Kinetic endovascular microincision creation prior to plain balloon angioplasty in real-world hemodialysis patients with vascular access dysfunction.
PubMed 文献 · J Vasc Surg · 2025-07-23

这项多中心观察性登记研究纳入130例因血管通路功能障碍计划行普通球囊血管成形术的血透患者,共176处病变在球囊扩张前接受动力学血管内微切开。术后1个月无严重不良事件,6个月靶病变一期通畅率为70.7%,动静脉瘘与人工血管分别为75.6%和55.2%,头静脉弓狭窄为76.3%,6个月二次通畅率为97.7%。

要点

  • 球囊扩张前动力学血管内微切开在血透通路狭窄中安全可行,术后1个月无严重不良事件。
  • 6个月靶病变一期通畅率70.7%,动静脉瘘75.6%优于人工血管55.2%。
  • 头静脉弓狭窄6个月靶病变一期通畅率76.3%,6个月二次通畅率97.7%。

核心结论

  • 在普通球囊经皮腔内血管成形术前行动力学血管内微切开,治疗血透动静脉瘘和人工血管的血流动力学显著狭窄安全有效,包括头静脉弓狭窄。

研究设计与样本

  • 多中心观察性登记研究,纳入130例因血管通路功能障碍计划行普通球囊血管成形术的血透患者,共治疗176处病变,随访至术后1、6、12个月。

主要发现

  • 靶病变长度为29 ± 21 mm,术前平均狭窄程度为75.4 ± 14.6%。
  • 1例因血管成形术相关术中夹层需要置入1枚覆膜支架,未观察到严重不良事件,1例受试者未完成随访评估。
  • 6个月靶病变一期通畅率为70.7%;动静脉瘘病例(n = 97)和人工血管病例(n = 32)分别为75.6%和55.2%。
  • 动静脉瘘头静脉弓狭窄(n = 35)的6个月靶病变一期通畅率为76.3%。
  • 6个月二次通畅率为97.7%。

关键数值与推荐

  • 主要安全性终点为术后1个月内无严重不良事件。
  • 主要疗效终点为术后6个月靶病变一期通畅率和免于临床驱动的靶病变血运重建。
  • 次要终点包括术后解剖成功、手术成功、临床成功、回路通畅率和二次通畅率。

临床怎么用

  • 对于血透动静脉瘘或人工血管的血流动力学显著狭窄,可在普通球囊血管成形术前先行动力学血管内微切开,以改善6个月靶病变一期通畅率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A large population of people with end-stage kidney disease relies on hemodialysis for renal replacement therapy. Dysfunction of hemodialysis access is common, yet current treatment with percutaneous transluminal balloon angioplasty to restore access functionality introduces concomitant short-term risk with a high rate of reintervention. This study was performed to assess the safety and efficacy of kinetic endovascular microincision creation before percutaneous transluminal balloon angioplasty with a plain (non-drug-coated) balloon, the predominant modality in real-world dialysis access interventions owing to its broad availability, favorable cost profile, and lack of payer parameters. METHODS: This multicenter observational registry enrolled hemodialysis patients who were scheduled for plain balloon angioplasty of their arteriovenous fistula (AVF) or graft owing to vascular access dysfunction. Follow-up occurred at 1, 6, and 12 months. The primary safety end point was freedom from serious adverse events through 1 month after the procedure. Primary efficacy end points at 6 months after the intervention were primary patency of the target lesion and freedom from clinically driven target lesion revascularization. Secondary end points were postprocedure anatomical success, procedural success, clinical success, circuit patency, and secondary patency. RESULTS: A total of 176 lesions were treated with kinetic endovascular microincisions before plain balloon angioplasty in 130 patients at 4 clinical sites. Target lesion characteristics were 29 ± 21 mm length with a mean preprocedure stenosis of 75.4 ± 14.6%. One stent graft was required for a single angioplasty-related procedural dissection; no serious adverse events were observed. One participant did not complete the follow-up evaluation. Six-month target lesion primary patency (TLPP) was 70.7%. TLPP for AVF cases (n = 97) and arteriovenous graft cases (n = 32) were 75.6% and 55.2%, respectively. For treatment of AVF cephalic arch stenosis (n = 35), 6-month TLPP was 76.3%. Six-month secondary patency was 97.7%. CONCLUSIONS: This registry demonstrates the safety and effectiveness of kinetic endovascular microincision creation before plain balloon percutaneous transluminal angioplasty to treat hemodynamically significant dialysis access stenoses of AVFs and arteriovenous grafts, including cephalic arch stenoses.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kramer A, Schultz SR, Altman SD, et al. Kinetic endovascular microincision creation prior to plain balloon angioplasty in real-world hemodialysis patients with vascular access dysfunction. J Vasc Surg. 2025. PMID: 40712843. doi:10.1016/j.jvs.2025.07.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。